You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
In Science this week: a review says lifestyles of industrialized societies may be threatening needed gut microbial communities, and more.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
The prime editing technique has strengths that are complementary to nuclease-based editing and base editing.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
The system uses the Cas13 nuclease to identify target sites in various RNA viruses and then destroy them.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The researchers repurposed type I variants of class 1 CRISPR systems to make them usable for DNA targeting and transcriptional control.
The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.